Design and Engineering of VesiVax HIV Immunogen Formulations

VesiVax HIV 免疫原制剂的设计和工程

• 批准号: 10213560
• 负责人: GARY FUJII
• 金额: $ 30万
• 依托单位: MOLECULAR EXPRESS, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10213560
• 关键词: Address; Affinity; Antibody Response; Antigen Targeting; Antigens; Attention; Chemicals; Development; Engineering; Formulation; HIV; HIV Envelope Protein gp120; HIV vaccine; HIV-1 vaccine; Liposomes; Messenger RNA; Nucleic Acids; RNA; Structure; Vaccine Research; Vesicle; base; design; env Gene Products; monomer; nanoparticle; nanoparticle delivery; neutralizing antibody; next generation; particle; vaccine candidate; vaccine development

Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen design and soluble antigens, the targeted and controlled delivery of antigens has not received much attention and is a gap in the HIV field that needs to be addressed. Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, selfamplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies.

基于颗粒的HIV免疫原共同递送作为下一代HIV疫苗：HIV疫苗研究的一个主要焦点是开发免疫原，引发针对包膜蛋白（Env）的广泛中和抗体反应。虽然该领域主要侧重于免疫原设计和可溶性抗原，但抗原的靶向和控制递送尚未受到太多关注，这是艾滋病毒领域需要解决的空白。量身定制的免疫原（如Envs、单体、天然和/或天然样三聚体、核酸/RNA，如mrna、自扩增RNA）与有效的多价抗原结合在纳米颗粒上进行递送，可能提供一种策略，以促进抗HIV的强效和长期的中和抗体反应，并直接对HIV中和抗体进行亲和成熟。